These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 6819018)

  • 1. Therapy of HBsAg-negative chronic active hepatitis in transfusion-dependent thalassemia major.
    De Virgiliis S; Argiolu F; Rais M; Cossu P; Toccafondi C; Sanna G; Cornacchia G; Nucaro A; Ferreli A; Cao A
    Birth Defects Orig Artic Ser; 1982; 18(7):355-60. PubMed ID: 6819018
    [No Abstract]   [Full Text] [Related]  

  • 2. Methyl-prednisolone treatment of serum HBsAg negative chronic active hepatitis occurring in transfusion-dependent thalassemia major.
    De Virgiliis S; Argiolu F; Rais M; Cossu P; Toccafondi C; Sanna G; Cornacchia G; Nucaro A; Bertolino F; Ferreli A
    Helv Paediatr Acta; 1983 Aug; 38(3):255-65. PubMed ID: 6618892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P
    Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunosuppressive therapy of chronic active hepatitis: results of a long-term follow-up].
    Musca A; Cordova C; Barnaba V; Levrero M; Zaccari C; Trinchieri F; Gnecchi M
    Clin Ter; 1983 Jun; 105(5):403-9. PubMed ID: 6872479
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 6. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 7. Complications of blood transfusion in thalassemia.
    Politis C
    Prog Clin Biol Res; 1989; 309():67-76. PubMed ID: 2550962
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment and prevention of hepatitis B and C in thalassemia.
    Mallat ME; Sharara AI
    Hemoglobin; 2009; 33 Suppl 1():S139-44. PubMed ID: 20001618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differences in the mechanism of development of HBsAg-positive and HBsAg-negative forms of chronic active hepatitis].
    Dzhalalova VA; Drozd TN; Beketova TP; Skriabina EG
    Klin Med (Mosk); 1986 Nov; 64(11):73-8. PubMed ID: 3821039
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of hepatitis-B virus markers in multi-transfused thalassemic patients.
    Mital MK; Vij JC; Talukdar B; Sachdev HP; Saini L
    Indian Pediatr; 1988 Feb; 25(2):161-5. PubMed ID: 3246395
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence of anti HCV, HBsAg and HIV antibodies in high risk recipients of blood and blood products.
    Chakrabarti S; Pradhan P; Roy A; Hira M; Bandyopadhyay G; Bhattacharya DK
    Indian J Public Health; 2006; 50(1):43-4. PubMed ID: 17193761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid therapy for chronic active hepatitis.
    Am J Gastroenterol; 1984 Jul; 79(7):573-5. PubMed ID: 6377879
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis B infection in multitransfused thalassaemics.
    George E; Ilina I; Yasmin AM; George R; Duraisamy G
    Med J Malaysia; 1988 Dec; 43(4):284-7. PubMed ID: 3241594
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunosuppressive therapy in patients with HBeAg-positive chronic active hepatitis B?].
    Maier KP; Lepiorz H; Berthold H; Gerok W
    Leber Magen Darm; 1982 Aug; 12(4):150-3. PubMed ID: 7132529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiviral therapy of HBsAg positive chronic hepatitis: progress or erroneous development?].
    Hess G
    Med Klin (Munich); 1987 May; 82(11):419-20. PubMed ID: 3600545
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 18. [Immunosuppressive treatment of patients with chronic active HBsAg positive hepatitis].
    Tanno H; Fay O; Roldán L; Vorovioff J
    Acta Gastroenterol Latinoam; 1982; 12(4):323-32. PubMed ID: 7185230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common transfusion-transmitted infectious agents among thalassaemic children in Bangladesh.
    Mollah AH; Nahar N; Siddique MA; Anwar KS; Hassan T; Azam MG
    J Health Popul Nutr; 2003 Mar; 21(1):67-71. PubMed ID: 12751676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B.
    Scullard GH; Smith CI; Merigan TC; Robinson WS; Gregory PB
    Gastroenterology; 1981 Dec; 81(6):987-91. PubMed ID: 7286593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.